Fuzhou Cornerstone Pharmaceutical Technology

Fuzhou Cornerstone Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative biologic therapies, particularly recombinant protein drugs. The company's lead candidate, F-652, is a first-in-class recombinant human interleukin-22 (IL-22) Fc fusion protein designed to treat inflammatory and tissue-damaging diseases. F-652 has been investigated in clinical trials for several high-need indications, including acute graft-versus-host disease (aGVHD), alcoholic hepatitis, and acute pancreatitis. The company leverages its expertise in protein engineering to create long-acting fusion proteins that enhance the therapeutic potential of cytokines. Fuzhou Cornerstone operates as an R&D-driven entity, often collaborating with larger partners to advance its pipeline through global clinical development.